Clinical Trials Logo

Clinical Trial Summary

This study investigates the effectiveness of a simple treatment to prevent proliferative vitreoretinopathy (PVR). Intraoperative intravitreal 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) is used as a prophylactic therapy in high-risk patients with primary rhegmatogenous retinal detachment (RRD). Our major motivation is to reduce the incidence of PVR in the group that receives the trial drug.


Clinical Trial Description

Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several attempts using chemotherapeutic agents have been undertaken to prevent this proliferation-process, but none of these was introduced into routine clinical practice. Until recently, it has been challenging to identify patients with high risk for postoperative PVR formation. This is especially important, because in this trial treatment with the trial drug will be restricted to patients at high risk for PVR only. Patients are assigned to the following treatment arms (1:1): (A) Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD). Versus: (B) Routinely used intraocular infusion with balanced salt solution (BSS) during routine PPV. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02834559
Study type Interventional
Source Universitätsklinikum Köln
Contact
Status Completed
Phase Phase 3
Start date October 27, 2016
Completion date June 15, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04403750 - Combined Laser-surgical Technology of RRD Treatment N/A
Not yet recruiting NCT04520789 - Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy N/A
Recruiting NCT04571788 - Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
Recruiting NCT01845571 - Retinal Detachment - Demographic and Clinical Survey
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Recruiting NCT02871531 - Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria N/A
Completed NCT00757536 - Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment N/A
Active, not recruiting NCT00370201 - Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Phase 3
Completed NCT00345007 - Macular Function After Scleral Buckle N/A
Recruiting NCT05331664 - Dropless Pars Plana Vitrectomy Study Phase 4
Completed NCT02841306 - Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment Phase 1
Not yet recruiting NCT02185469 - Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment N/A
Not yet recruiting NCT01647373 - Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling N/A
Completed NCT01068379 - Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation Phase 3
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Not yet recruiting NCT06468397 - Acute Retinal Detachment Repair With the iSeelr^TM Retinal Detachment Repair System N/A
Recruiting NCT06056596 - Lamivudine and Plasma Markers of Inflammation in Retinal Detachment Early Phase 1
Completed NCT01343134 - Anatomical and Functional Macular Changes in Retinal Detachment N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A
Completed NCT03542162 - Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment N/A